You are here: Industry Insights > CVnCoV

News List

CureVac provides update on Phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV worldpharmanews
June 21, 2021
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced results of the second interim analysis of its international pivotal Phase 2b/3 study in ...
CureVac’s COVID-19 vaccine misses the mark in late-stage study pharmatimes
June 18, 2021
German biopharma company CureVac has announced that its COVID-19 vaccine candidate CVnCoV missed the prespecified statistical success criteria in a Phase II/III study.
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation firstwordpharma
May 31, 2021
CVAC today announced that the independent DSMB has confirmed that the pivotal Phase 2b/3 study for CureVac's first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases.
CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic worldpharmanews
April 26, 2021
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission for CVnCoV ...
CureVac, Celonic Enter COVID-19 Vax Mfg. Pact contractpharma
March 31, 2021
Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year at Heidelberg facility.
CureVac Expands Late-stage Trials of COVID Vax Candidate contractpharma
March 23, 2021
CureVac N.V. plans to expand and further specify the protocols of its ongoing late-stage clinical trials with its COVID-19 vaccine candidate, CVnCoV.
CureVac, Novartis Ink COVID Vax Mfg. Pact contractpharma
March 05, 2021
Novartis to manufacture the mRNA and bulk drug product of the CVnCoV vaccine for up to 50 million doses by the end of 2021.
CureVac’s COVID-19 vaccine begins rolling review with EMA pharmatimes
February 19, 2021
German biopharmaceutical company CureVac has announced the initiation of a rolling review with the European Medicines Agency (EMA) for its mRNA-based COVID-19 vaccine, CVnCoV.
CureVac & Rentschler Biopharma Collaborate on Vaccine contractpharma
February 09, 2021
CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for ...
GSK, CureVac Enter New €150M COVID Vax Pact contractpharma
February 04, 2021
GSK will support the manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021.

Previous page 1 2 Next page